Keywords: XOMA Corp, XmetA, Glycemic control
XOMA's allosteric insulin receptor-activating antibody first to improve glycemic control in vivo
Article | 12 March 2012
US therapeutic antibody discovery firm XOMA Corp (Nasdaq: XOMA) announced that results from a study of XMetA, the company's fully-human ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
